Cg Oncology (CGON) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Cg Oncology (CGON).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | 1.08M (-53.45%) | 2.32M (+38.92%) | 1.67M | - | 50K (-89.13%) | 460K (+1050.00%) | 40K (-63.64%) | 110K (-79.25%) | 530K | - | 10K | - | 190K |
Operating Expenses | |||||||||||||
Research And Development | 44M (+45.96%) | 30M (+7.46%) | 28M (-11.01%) | 31M (+14.05%) | 27M (+2.50%) | 27M (+36.60%) | 20M (+6.23%) | 18M (+7.32%) | 17M (+5.32%) | 16M (+39.18%) | 12M (+19.43%) | 9.83M (+25.38%) | 7.84M |
Selling General And Administrative | 21M (+15.51%) | 18M (-22.89%) | 23M (+34.00%) | 17M (+17.71%) | 15M (+26.30%) | 12M (+34.29%) | 8.72M (+16.42%) | 7.49M (+29.36%) | 5.79M (+91.72%) | 3.02M (+30.17%) | 2.32M (-6.83%) | 2.49M (+20.29%) | 2.07M |
Operating Expenses | 65M (+34.54%) | 48M (-6.38%) | 51M (+5.09%) | 49M (+15.33%) | 42M (+9.74%) | 39M (+35.89%) | 28M (+9.17%) | 26M (+12.87%) | 23M (+18.80%) | 19M (+37.79%) | 14M (+13.95%) | 12M (+24.42%) | 9.91M |
Depreciation And Amortization | 840K (-8.70%) | 920K (+84.00%) | 500K | - | 20K (-33.33%) | 30K | - | - | - | 10K | - | - | - |
Operating Income | |||||||||||||
Operating Income | -66.39M (+36.32%) | -48.70M (-4.75%) | -51.13M (+4.90%) | -48.74M (+15.50%) | -42.20M (+10.91%) | -38.05M (+34.50%) | -28.29M (+9.44%) | -25.85M (+15.04%) | -22.47M (+16.06%) | -19.36M (+37.89%) | -14.04M (+13.87%) | -12.33M (+26.85%) | -9.72M |
Ebit | -66.39M (+36.32%) | -48.70M (-4.75%) | -51.13M (+4.90%) | -48.74M (+15.50%) | -42.20M (+10.91%) | -38.05M (+34.50%) | -28.29M (+9.44%) | -25.85M (+15.04%) | -22.47M (+16.06%) | -19.36M (+37.89%) | -14.04M (+13.87%) | -12.33M (+26.85%) | -9.72M |
EBITDA | -65.55M (+18.99%) | -55.09M (+8.81%) | -50.63M (+22.21%) | -41.43M (-1.78%) | -42.18M (-20.20%) | -52.86M (+159.12%) | -20.40M (+7.94%) | -18.90M (-15.85%) | -22.46M (+0.58%) | -22.33M (+89.72%) | -11.77M (+1.38%) | -11.61M (+19.44%) | -9.72M |
Other Income / Expenses | |||||||||||||
Interest Income | 6.29M (-15.46%) | 7.44M (+0.27%) | 7.42M (+1.37%) | 7.32M (-5.55%) | 7.75M (+24.00%) | 6.25M (-20.79%) | 7.89M (+13.69%) | 6.94M (+25.27%) | 5.54M (+97.86%) | 2.80M (+22.81%) | 2.28M (+196.10%) | 770K (-26.67%) | 1.05M |
Net Interest Income | 6.29M (-15.46%) | 7.44M (+0.27%) | 7.42M (+1.37%) | 7.32M (-5.55%) | 7.75M (+24.00%) | 6.25M (-20.79%) | 7.89M (+13.69%) | 6.94M (+25.27%) | 5.54M (+97.86%) | 2.80M (+22.81%) | 2.28M (+196.10%) | 770K (-26.67%) | 1.05M |
Other Non Operating Income | -100.00K (-33.33%) | -150.00K (+50.00%) | -100.00K | - | 10K | - | - | 10K | -10.00K (-83.33%) | -60.00K (+500.00%) | -10.00K (-83.33%) | -60.00K | 10K |
Net Income | |||||||||||||
Income Tax Expense | - | -270.00K | - | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -60.20M (+45.73%) | -41.31M (-5.71%) | -43.81M (+5.74%) | -41.43M (+20.26%) | -34.45M (+8.33%) | -31.80M (+55.88%) | -20.40M (+7.94%) | -18.90M (+11.64%) | -16.93M (+2.30%) | -16.55M (+40.61%) | -11.77M (+1.38%) | -11.61M (+33.91%) | -8.67M |
Net Income | -60.20M (+45.73%) | -41.31M (-5.71%) | -43.81M (+5.74%) | -41.43M (+20.26%) | -34.45M (+8.33%) | -31.80M (+55.88%) | -20.40M (+7.94%) | -18.90M (+11.64%) | -16.93M (+2.30%) | -16.55M (+40.61%) | -11.77M (+1.38%) | -11.61M (+33.91%) | -8.67M |